Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Critical appraisal of the European Union Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) Preliminary Opinion on electronic cigarettes

View ORCID ProfileR. O’Leary, View ORCID ProfileR. Polosa, G. Li Volti on behalf of the CoEHAR study group
doi: https://doi.org/10.1101/2020.11.09.20228296
R. O’Leary
CoEHAR (Center of Excellence for the Acceleration of Harm Reduction), University of Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R. O’Leary
R. Polosa
CoEHAR (Center of Excellence for the Acceleration of Harm Reduction), University of Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R. Polosa
  • For correspondence: polosa@unict.it
G. Li Volti
CoEHAR (Center of Excellence for the Acceleration of Harm Reduction), University of Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CoEHAR (Center of Excellence for the Acceleration of Harm Reduction), University of Catania, Italy
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background In preparation for the 2021 revision of the European Union Tobacco Products Directive, the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) has posted its Preliminary Opinion on Electronic Cigarettes. They conclude that e-cigarettes only achieve a sub-optimal level of protection of human health. In this paper we provide evidence that Opinion’s conclusions are not adequately backed up by scientific evidence and totally disregard the potential health benefits of using alternative combustion-free nicotine containing products as substitute for tobacco cigarettes.

Method Searches for articles were conducted in PubMed and by citation chasing in Google Scholar. Articles were also retrieved with a review of references in major publications. Primary data from World Health Organization surveys, the conclusions of reviews, and peer-reviewed non-industry studies were cited to address errors and omissions identified in the Opinion.

Results The Opinion omitted reporting on the individual and population health benefits of the substitution of e-cigarettes (ENDS) for cigarette smoking. Alternative hypotheses to the gateway theory were not evaluated. Its assessment of cardiovascular risk is contradicted by numerous reviews. It exhibits biases in its statements from the measurements selected on the frequency of use. It did not report non-nicotine use. It misrepresented trends in ENDS prevalence. It over-emphasized the role of flavours in youth ENDS initiation. It did not discuss cessation in sufficient length.

Conclusions For the delivery of a robust and comprehensive final report, the members of the Working Group of the Scientific Committee on Health, Environmental and Emerging Risks will need to consider (1) the potential health benefits of ENDS substitution for cigarette smoking, (2) alternative hypotheses and contradictory studies on the gateway effect, (3) its assessment of cardiovascular risk, (4) biases arising from the measurements of frequency of use, (5) non-nicotine use, (6) the role of flavours, and (7) a fulsome discussion of cessation.

Competing Interest Statement

RO is supported by a contract from ECLAT srl a spin-off of the University of Catania Italy as a Project Leader for a literature review research project she independently developed and submitted to the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR). CoEHAR has received a grant from the Foundation for a Smoke-Free World for the research project. She declares no conflict of interest. RP is full-time employee of the University of Catania, Italy. In relation to his work in the area of tobacco control and respiratory diseases, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, NeuroSearch A/S, Boehringer Ingelheim, Novartis, Duska Therapeutics, Alfa-Wassermann, Forest Laboratories, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP is the Founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from Foundation for a Smoke Free World to develop and carry out 8 research projects. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League) and Chair of the European Technical Committee for standardization on Requirements and test methods for emissions of electronic cigarettes (CEN/TC 437; WG4). GLV is full professor of biochemistry at University of Catania and he is currently chairman of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from the Foundation for a Smoke Free World to support 8 independent investigator-initiated research projects on tobacco harm reduction.

Clinical Trial

not a clinical trial

Funding Statement

No funding was received for this article.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB not required

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data for Tables 1, 2, 3, and 7 were extracted from the published articles cited as the source. Data for Table 4 is from the Passport database and is not publicly available. It is available only by subscription from EUROMONITOR International, London, a privately owned market research company. The company can be contacted at https://www.euromonitor.com/ Data for Tables 5 and 6 are from the Global Youth Tobacco Surveys with open access at the World Health Organization NCD Microdata Repository: https://extranet.who.int/ncdsmicrodata/index.php/home.

https://www.euromonitor.com/

https://extranet.who.int/ncdsmicrodata/index.php/home

  • List of Abbreviations

    BP
    blood pressure
    CI 95%
    confidence interval
    COPD
    chronic obstructive pulmonary disease ENDS electronic nicotine delivery system(s)
    ESPAD
    European School Survey Project on Alcohol and Other Drugs
    EU
    European Union
    GYTS
    Global Youth Tobacco Survey
    N
    total number of participants
    n
    subset of participants NR not reported
    NYTS US
    National Youth Tobacco Survey
    PATH US
    Population Assessment of Tobacco and Health Survey RR relative risk
    RRR
    relative risk ratio
    US
    United States
    WHO
    World Health Organization
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted November 10, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Critical appraisal of the European Union Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) Preliminary Opinion on electronic cigarettes
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Critical appraisal of the European Union Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) Preliminary Opinion on electronic cigarettes
    R. O’Leary, R. Polosa, G. Li Volti
    medRxiv 2020.11.09.20228296; doi: https://doi.org/10.1101/2020.11.09.20228296
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Critical appraisal of the European Union Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) Preliminary Opinion on electronic cigarettes
    R. O’Leary, R. Polosa, G. Li Volti
    medRxiv 2020.11.09.20228296; doi: https://doi.org/10.1101/2020.11.09.20228296

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Public and Global Health
    Subject Areas
    All Articles
    • Addiction Medicine (179)
    • Allergy and Immunology (433)
    • Anesthesia (99)
    • Cardiovascular Medicine (946)
    • Dentistry and Oral Medicine (178)
    • Dermatology (109)
    • Emergency Medicine (260)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
    • Epidemiology (8978)
    • Forensic Medicine (4)
    • Gastroenterology (419)
    • Genetic and Genomic Medicine (1947)
    • Geriatric Medicine (190)
    • Health Economics (401)
    • Health Informatics (1327)
    • Health Policy (657)
    • Health Systems and Quality Improvement (519)
    • Hematology (212)
    • HIV/AIDS (419)
    • Infectious Diseases (except HIV/AIDS) (10793)
    • Intensive Care and Critical Care Medicine (575)
    • Medical Education (200)
    • Medical Ethics (54)
    • Nephrology (222)
    • Neurology (1824)
    • Nursing (109)
    • Nutrition (272)
    • Obstetrics and Gynecology (352)
    • Occupational and Environmental Health (470)
    • Oncology (997)
    • Ophthalmology (297)
    • Orthopedics (111)
    • Otolaryngology (182)
    • Pain Medicine (126)
    • Palliative Medicine (44)
    • Pathology (265)
    • Pediatrics (579)
    • Pharmacology and Therapeutics (275)
    • Primary Care Research (234)
    • Psychiatry and Clinical Psychology (1895)
    • Public and Global Health (4117)
    • Radiology and Imaging (675)
    • Rehabilitation Medicine and Physical Therapy (366)
    • Respiratory Medicine (548)
    • Rheumatology (224)
    • Sexual and Reproductive Health (190)
    • Sports Medicine (177)
    • Surgery (207)
    • Toxicology (39)
    • Transplantation (109)
    • Urology (80)